The CANTREAT trial found a treat-and-extend strategy with ranibizumab for patients with neovascular age-related macular degeneration was not worse than treatment with monthly injections after 2 years, according to a study.
“Our goal in treating macular degeneration, the most common cause of blindness in the Western world, is to maximize visual gains and minimize the burden of treatment and visits on patients and their families. This most recent Canadian Treat-and-Extend study (CANTREAT) publication shows definitively that patients randomized to a treat-and-extend regimen had similar outcomes to those randomized to monthly treatment at 24 months,” study co-author Peter J. Kertes, MD, CM, told Healio/OSN.
The trial included 580 patients who were randomly assigned to receive intravitreal Lucentis (ranibizumab 0.5 mg, Genentech) in either a treat-and-extend regimen or monthly dosing regimen. Researchers evaluated the mean change in best corrected visual acuity in ETDRS letters from baseline to 24 months as the primary outcome measure.
At 24 months, the treat-and-extend cohort gained 6.8 letters in BCVA compared with 6 letters in the monthly treatment cohort. The proportion of patients who gained less than 5 letters, including a loss of letters, at 24 months was 38.1% in the treat-and-extend cohort compared with 40.4% of patients in the monthly cohort. A gain of 15 or more letters was seen in 25.5% of patients in the treat-and-extend cohort compared with 23.1% in the monthly cohort.
Patients in the treat-and-extend cohort underwent a mean 17.6 injections over the 24-month period compared with 23.5 injections in the monthly cohort. – by Robert Linnehan
Disclosure : Kertes reports he receives grants, personal fees and nonfinancial support from Novartis; receives personal fees and nonfinancial support from Bayer; receives grants from Allergan and Roche; and holds stock in ArcticDx.